IVF-AI
About
What does IVF-AI do?
IVF-AI is a medical startup based in Israel with the vision of democratizing IVF procedures. They aim to increase accessibility and success rates of IVF treatments, irrespective of a patient's location, knowledge, or financial capabilities, by leveraging technology to transform the IVF process.
What is IVF-AI's revenue?
StartupHub estimates IVF-AI's annual revenue at $343K (range $259K to $924K, 68% confidence), based on comparable companies in the sector.
Where is IVF-AI headquartered?
IVF-AI is headquartered in Tel Aviv, Israel.
When was IVF-AI founded?
IVF-AI was founded in 2020.
What industry does IVF-AI operate in?
IVF-AI operates in Healthcare, InVitro Fertilization (IVF), HealthTech, MedTech, Biotech, Clinical Trials.
How many employees does IVF-AI have?
IVF-AI has approximately 2 people on record.
What is IVF-AI's current status?
IVF-AI's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.